Holding(s) in Company

Oxford Biomedica PLC
20 June 2024
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BDFBVT43

Issuer Name

OXFORD BIOMEDICA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Institut Merieux SA

City of registered office (if applicable)

Lyon

Country of registered office (if applicable)

France

4. Details of the shareholder

Name

City of registered office

Country of registered office

Natixis

Paris

France

5. Date on which the threshold was crossed or reached

19-Jun-2024

6. Date on which Issuer notified

19-Jun-2024

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

10.934389

0.000000

10.934389

11,510,481

Position of previous notification (if applicable)

6.151995

0.000000

6.151995

6149374

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BDFBVT43

11,510,481

0

10.934389%

0.000000

Sub Total 8.A

11,510,481

10.934389%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 





Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 






Sub Total 8.B2




9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Institut Merieux SA

TSGH SAS

10.934389%

0.000000

10.934389%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

TSGH SAS (a wholly owned subsidiary of Institut Merieux SA) holds the shares in Oxford Biomedica Plc through a securities account of the French corporate and investment bank, Natixis (the ''Shareholder''). Institut Merieux SA has control and discretion over the voting rights attaching to the shares of Oxford Biomedica Plc, which are held by the Shareholder, through its ownership of the equity of TSGH SAS.

12. Date of Completion

19 June 2024

13. Place Of Completion

United Kingdom

 

Contact name:

Natalie Walter

Contact phone number:

01865 783 000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings